Li-Han Chin Selected Research

Cysteine-Rich Protein 61

1/2017	Correction: Combined Treatment with Troglitazone and Lovastatin Inhibited Epidermal Growth Factor-Induced Migration through the Downregulation of Cysteine-Rich Protein 61 in Human Anaplastic Thyroid Cancer Cells.
5/2016	Involvement of cysteine-rich protein 61 in the epidermal growth factor-induced migration of human anaplastic thyroid cancer cells.
1/2015	Combined treatment with troglitazone and lovastatin inhibited epidermal growth factor-induced migration through the downregulation of cysteine-rich protein 61 in human anaplastic thyroid cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Li-Han Chin Research Topics

Disease

4	Anaplastic Thyroid Carcinoma 01/2018 - 01/2015
2	Neoplasms (Cancer) 01/2020 - 01/2018
2	Chronic Renal Insufficiency 01/2020 - 12/2017
1	Neoplasm Metastasis (Metastasis) 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Adenocarcinoma of Lung 01/2020
1	Thyroid Neoplasms (Thyroid Cancer) 05/2016

Drug/Important Bio-Agent (IBA)

3	Troglitazone (Rezulin)FDA Link 01/2018 - 01/2015
3	Lovastatin (Mevacor)FDA LinkGeneric 01/2018 - 01/2015
3	Epidermal Growth Factor (EGF)IBA 01/2017 - 01/2015
3	Cysteine-Rich Protein 61IBA 01/2017 - 01/2015
1	Tyrosine Kinase InhibitorsIBA 01/2020
1	CalciumIBA 01/2020
1	Pharmaceutical PreparationsIBA 01/2020
1	PPAR gammaIBA 01/2018
1	Oxidoreductases (Dehydrogenase)IBA 01/2018
1	Coenzyme A (CoA)IBA 01/2018
1	InflammasomesIBA 12/2017

Therapy/Procedure

1	Therapeutics 01/2020
1	Aftercare (After-Treatment) 01/2020